The overall concordance between the IdyllaTM KRAS Mutation Assay and the confirmed reference routine test results for colorectal cancer samples was found to be 98.9%, with a negative percent agreement of 99.25% and a positive percent agreement of 98.68%. The gene discussed is KRAS; the disease is colorectal cancer.